A phase II trial suggests that anti-CD38 antibody daratumumab is effective as a standalone therapy for heavily treated multiple myeloma. In a group of 106 patients whose disease worsened after at least three prior treatments, nearly one in three responded to daratumumab, and disease progression was delayed by 3.7 months, on average. The estimated one-year overall survival rate was 65%.
Presented by Saad Zafar Usmani, MD, Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC, at ASCO 2015
European Medical Journal